Key statistics
As of last trade, Liquidia Corp (LQDA:NAQ) traded at 9.82, 71.98% above the 52 week low of 5.71 set on Oct 19, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 9.87 |
---|---|
High | 9.95 |
Low | 9.73 |
Bid | 9.80 |
Offer | 9.83 |
Previous close | 9.95 |
Average volume | 1.15m |
---|---|
Shares outstanding | 84.00m |
Free float | 67.62m |
P/E (TTM) | -- |
Market cap | 835.79m USD |
EPS (TTM) | -1.57 USD |
Data delayed at least 15 minutes, as of Sep 23 2024 15:24 BST.
More ▼
- Court Finds United Therapeutics’ Interference with Launch of Generic Treprostinil Injection Caused Losses of More Than $137 Million
- Liquidia Corporation Announces Raise of $67.5 Million from New Common Stock Financings and $32.5 Million Advance from HealthCare Royalty Under Current Financing Agreement
- Liquidia to Present at Upcoming Investor Conferences
- Liquidia Files Litigation to Challenge Regulatory Exclusivity Blocking Access to YUTREPIA™ (treprostinil) inhalation powder for Patients Suffering with PAH and PH-ILD
- U.S. FDA Grants Tentative Approval of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
- Liquidia Announces Poster Presentations at the PHA 2024 International PH Conference and Scientific Sessions
- Liquidia Corporation Reports Second Quarter 2024 Financial Results and Provides Corporate Update
- Liquidia Corporation to Report Second Quarter 2024 Financial Results on August 7, 2024
- Liquidia Announces Poster Presentations at the 7th World Symposia on Pulmonary Hypertension (WSPH)
- District Court Issues Favorable Ruling and Denies United Therapeutics’ Request to Block YUTREPIA™ Launch
More ▼